FANJ
RIGL icon

Financial Architects (New Jersey)’s Rigel Pharmaceuticals RIGL Stock Holding History

Financial Architects (New Jersey)’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,500
Closed -$33K – 1494
2016
Q2 		$33K Hold
1,500
– – 0.01% 646
2016
Q1 		$31K Hold
1,500
– – 0.01% 494
2015
Q4 		$45K Hold
1,500
– – 0.02% 212
2015
Q3 		$37K Hold
1,500
– – 0.02% 202
2015
Q2 		$48K Hold
1,500
– – 0.02% 447
2015
Q1 		$54K Buy
+1,500
New +$41.1K 0.02% 389

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Financial Architects (New Jersey)'s RIGL Position: Q3 2016 in Review

Financial Architects (New Jersey) sold out of Rigel Pharmaceuticals (RIGL) in Q3 2016, closing a stake of 1,500 shares — an estimated $33K sold.

Financial Architects (New Jersey) first reported a position in RIGL in Q1 2015 and held it in 6 quarters. The position peaked at $54K in Q1 2015. 121 funds tracked by Wall St. Rank hold RIGL as of Q3 2016.

  • Financial Architects (New Jersey) reported no remaining Rigel Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 1,500 Rigel Pharmaceuticals shares in Q3 2016, an estimated $33K.
  • Financial Architects (New Jersey) first reported a position in Rigel Pharmaceuticals in Q1 2015 and held it in 6 quarters.
  • Financial Architects (New Jersey)'s Rigel Pharmaceuticals position peaked at $54K in Q1 2015.
  • 121 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2016.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2016, filed 28 Oct 2016.